Anavex Life Sciences Announces Presentations at the IRSF Rett Syndrome Scientific Meeting

Anavex Life Sciences Provides Supplemental Information on ANAVEX®2-73 AVATAR Phase 3 Trial

ANAVEX®2-73 (Blarcamesine) AVATAR Phase 3 Trial met Primary and Secondary Efficacy Endpoints

Anavex Life Sciences Announces Participation at Worldwide NIH Panel at Rare Disease Day®

Anavex Life Sciences Announces Webinar on Rett Syndrome and ANAVEX®2-73 (Blarcamesine) Phase 2 Data

Anavex Life Sciences Announces Completion of ANAVEX®2-73 U.S. Phase 2 Rett Syndrome Clinical Trial